ADC Therapeutics

ADCTApproved

ADC Therapeutics is a Switzerland-based biopharmaceutical company dedicated to transforming cancer treatment through its focused portfolio of antibody-drug conjugates. The company has achieved commercial success with ZYNLONTA®, an FDA-approved anti-CD19 ADC for specific types of large B-cell lymphoma, and is actively pursuing label expansion for this product. Concurrently, ADC Therapeutics is advancing its pipeline, including a promising PSMA-targeting ADC for solid tumors, aiming to deliver more effective and targeted therapies for patients with difficult-to-treat cancers.

Market Cap

$490.4M

Focus

AntibodiesBiologicsSmall Molecules

ADCT · Stock Price

USD 3.869.45 (-71.00%)

Historical price data

AI Company Overview

Technology Platform

Proprietary antibody-drug conjugate (ADC) platform featuring targeted monoclonal antibodies linked to potent cytotoxic payloads (including PBD dimers and exatecan-based topoisomerase I inhibitors) via novel, stable linkers designed to improve therapeutic index.

Pipeline Snapshot

31 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Loncastuximab Tesirine + Rituximab + Gemcitabine + Oxaliplatin	Relapsed Diffuse Large B-Cell Lymphoma	Phase 3
Loncastuximab Tesirine + Idelalisib	Relapsed Follicular Lymphoma	Phase 2
Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg	Marginal Zone Lymphoma	Phase 2
Loncastuximab tesirine + Rituximab	Follicular Lymphoma	Phase 2
Loncastuximab Tesirine + Rituximab	Relapsed or Refractory Large B-cell Lymphoma	Phase 2

FDA Approved Drugs

ZYNLONTABLAApr 23, 2021

Opportunities

Significant growth opportunities exist through the geographic and label expansion of ZYNLONTA® into earlier lines of therapy for large B-cell lymphoma.

Furthermore, the successful development of its next-generation PSMA-targeting ADC could open a large new market in prostate cancer and other solid tumors, leveraging a validated target with a novel therapeutic modality.

Risk Factors

Key risks include commercial execution challenges for ZYNLONTA® against strong competition, clinical trial failures in label expansion or pipeline programs, and financial sustainability as the company works towards profitability.

The competitive ADC landscape also poses a constant threat of newer, more effective technologies.

Competitive Landscape

ADC Therapeutics competes directly with other ADC and oncology therapy developers, including large pharma like AstraZeneca, Pfizer, and Roche, as well as biotechs in the lymphoma and prostate cancer spaces. Its differentiation is based on its specific linker-payload technology (e.g., PBD dimers, exatecan payloads) and focused development strategy in areas of high unmet need.

Publications

Patents

Pipeline

FDA Approvals